BioDelivery Sciences International (NASDAQ:BDSI), A increase of 61,489 shares or 0.6% was observed in the short interest of BioDelivery Sciences International, Inc. The interest on June 15,2016 came in at 10,395,485 shares and as per the average daily trading of 1,148,932 shares, the days to cover are 9. The increased interest is 21.6% of the floated shares. The data of May 31,2016 put the interest at 10,333,996 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
BioDelivery Sciences International (NASDAQ:BDSI): The stock opened at $2.23 on Friday but the bulls could not build on the opening and the stock topped out at $2.34 for the day. The stock traded down to $2.19 during the day, due to lack of any buying support eventually closed down at $2.27 with a loss of -5.02% for the day. The stock had closed at $2.39 on the previous day. The total traded volume was 6,023,771 shares.
The company shares have dropped -68.73% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $9.91 and the one year low was seen on May 23, 2016. The 50-Day Moving Average price is $2.28 and the 200 Day Moving Average price is recorded at $3.46.
BioDelivery Sciences International (NASDAQ:BDSI) has tumbled 5.02% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 7.58% in the last four weeks. The stocks have underperformed the S&P 500 by 3.44% during the past week but BioDelivery Sciences International (NASDAQ:BDSI) it has outperformed the index in 4 weeks by 10.84%.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.